If you’ve ever looked at GH peptides and wondered why the rankings seem to contradict each other, this is why.

In my latest GH deep dive, I ended up with two different charts that seemed to point in slightly different directions.

One chart looked at the real-world outcomes people care about most:

fat loss, muscle, sleep, recovery, health risks, and cost.

The other looked at something more fundamental:

how much growth hormone signaling each compound appears to generate over time.

At first, those charts looked like they were in tension.

Tesamorelin looked strong for fat loss.
CJC-1295 DAC looked stronger for sustained GH and IGF-1 exposure.
Ipamorelin combos had a reputation for better sleep and recovery.
And HGH sat above everything.

So what actually matters here?

After digging deeper into the literature, my current view is this:

both total GH exposure and pulsatility matter.

And they do not seem to matter equally for every outcome.

The simplest mistake would be to assume pulse structure is everything.

It isn’t.

Higher average GH exposure still appears to matter a lot. It likely drives a more anabolic environment, more IGF-1 signaling, and a lot of the broad tissue-repair and recovery effects people associate with the GH axis.

And yes — it likely contributes substantially to fat loss too.

That matters because compounds like HGH and CJC-1295 DAC can create a much larger average GH / IGF-1 signal over time than shorter pulse-based secretagogues.

So if one compound is producing dramatically more total GH exposure, it is hard to believe pulsatility alone would fully overcome that gap.

This is where Tesamorelin becomes interesting.

Human studies comparing continuous GH delivery to pulsatile GH delivery at the same total dose found that continuous exposure produced a bigger rise in IGF-1, but pulsatile delivery produced more lipolysis.

That means pulse pattern changes how GH’s effects are expressed.

So the reason Tesamorelin performs well in visceral-fat studies may not simply be that it raises GH.

It may be that it raises GH in a more physiologic, pulse-preserving way that is especially favorable for fat mobilization.

Tesamorelin has some of the strongest direct human data for reducing visceral adipose tissue.

It also increases both basal and pulsatile GH secretion, rather than simply flattening GH into a constant signal.

That makes it more than just “more GH.”

But it also does not prove that a lower total GH exposure can always beat a much higher one simply because the pulse pattern is prettier.

That leap goes beyond the evidence.

At this point, the simplest framework is this:

Fat loss: driven by both total GH exposure and pulse pattern
Muscle / recovery / anabolic environment: probably lean more toward total GH / IGF-1 exposure
Sleep: depends most clearly on pathway and timing, not just GH level

That last point matters because the older chart leaned too hard on peptide reputation. Human sleep data suggest the GHRH pathway has a clearer relationship to slow-wave sleep than the GHRP / ghrelin side.

So more GH does not automatically equal better sleep.

That also helps explain why the earlier comparison chart and the newer exposure chart seemed to disagree.

The earlier chart mixed:

The newer chart was more mechanistic.

So the best synthesis is not that one chart was right and the other was wrong.

It’s that the earlier chart captured some real-world pattern recognition, while the newer chart forced a more honest question:

how much of what people attribute to these compounds is really just a function of total GH exposure over time?

My answer now is:

a lot of it probably is.

But not all of it.

If the goal is directly supported visceral-fat reduction, Tesamorelin still has the strongest evidence.

If the goal is maximizing sustained GH / IGF-1 exposure at a much lower cost, CJC-1295 DAC becomes much more compelling than I originally gave it credit for.

And if the goal is simply understanding the GH axis correctly, the answer is not “pulsatility versus exposure.”

It’s:

exposure does most of the heavy lifting, while pulse pattern can meaningfully bias the fat-loss side of the equation.

Note: This ranking is subjective. I prioritized lipolysis, treating total GH exposure as the primary lever and pulsatility as an enhancer. Between Tesamorelin and CJC-1295 (DAC), cost broke the tie for me. Use the chart to make your own decision based on your priorities.

Even when these compounds work, the results are not automatically permanent.

In Tesamorelin studies, visceral-fat reductions were maintained during treatment, but tended to fade after discontinuation.

That tells us something important:

these compounds help create a better hormonal environment, but they do not permanently fix the system that caused the fat gain in the first place.

Which is exactly why the drug alone is never the whole answer.

Without the right training, food, activity, and metabolic habits, the improvements drift backward.

That’s why I built 75 Days to Shredded in the first place.

Because if you want to hold onto the gains, you need a system that keeps working after the compound is gone.

75 Days to Shredded is the exact zero-BS system I used at 47 to lose 25 lb of fat and gain 6 lb of muscle.